Zoetis Inc. $ZTS Shares Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 371.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,013 shares of the company’s stock after purchasing an additional 46,501 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Zoetis were worth $9,203,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Nova Wealth Management Inc. acquired a new position in shares of Zoetis in the first quarter worth $25,000. 1248 Management LLC acquired a new position in Zoetis in the 1st quarter valued at about $27,000. Saudi Central Bank acquired a new position in Zoetis in the 1st quarter valued at about $29,000. Cornerstone Planning Group LLC raised its stake in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares during the last quarter. Finally, REAP Financial Group LLC raised its stake in Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ZTS. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research report on Friday. Argus reiterated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Piper Sandler boosted their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $195.00.

Zoetis Stock Performance

Shares of ZTS stock opened at $146.14 on Monday. Zoetis Inc. has a one year low of $139.34 and a one year high of $184.40. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The company has a 50 day moving average price of $148.18 and a 200 day moving average price of $153.57. The firm has a market capitalization of $64.77 billion, a price-to-earnings ratio of 25.15, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.4%. Zoetis’s dividend payout ratio is currently 34.42%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.